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ABSTRACT 
Drug resistance to conventional anticancer therapies is almost inevitable in 
patients with advanced ovarian cancer, limiting their available treatment 
options. Novel phase I trial therapies within a dedicated drug development 
unit may represent a viable alternative; however, there is currently little 
evidence for patient outcomes in such patients. To address this, we undertook 
a retrospective review of patients with advanced ovarian cancer allocated to 
phase I trials in the Drug Development Unit at Royal Marsden Hospital (RMH) 
between 06/1998 and 10/2010.  A total of 200 AOC patients with progressive 
disease were allocated to ≥1 trial each, with a total of 281 allocations. Of 
these, 135 (68%) patients commenced ≥1 trial (mean 1.4 [1-8]), totaling 216 
allocated trials; 65 (32%) patients did not start due to deterioration resulting 
from rapidly progressive disease (63 patients) or patient choice (2 patients). 
RECIST complete/partial responses (CR/PR) were observed in 43 (20%) of 
those starting trials, including those on poly(ADP-ribose) polymerase (PARP) 
inhibitors (18/79 [23%]), anti-angiogenics (9/65 [14%]) and chemotherapy 
combinations (14/43 [33%]). Factors associated with CR/PR included: fewer 
prior treatments, platinum-sensitive disease, CR/PR with prior therapy, ECOG 
performance status, fewer metastatic sites, higher albumin and hemoglobin 
levels, lower white cell counts and baseline CA125 levels, germline BRCA1/2 
mutation and better RMH Prognostic Score. Mean survival was 32 months for 
patients who achieved CR/PR. Treatments were generally well tolerated. Most  
patients with advanced ovarian cancer (134/200 [67%]) received ≥1 
subsequent lines of therapy after Phase I trials. Our data suggest that phase I 
trial referrals should be considered earlier in the advanced ovarian cancer 
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treatment pathway, and before the onset of rapid PD particularly with the 
emergence of promising novel agents in the era of precision medicine.
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INTRODUCTION 
Ovarian cancer is the fifth most common malignancy in the UK, with more 
than 7000 women diagnosed each year [1]. The majority of patients are 
diagnosed with advanced stage disease, and despite good initial responses to 
standard chemotherapy regimens, most will inevitably develop drug 
resistance leading to disease progression. For such women, phase I trials 
represent an opportunity to access new anticancer treatments that are at early 
stages of clinical development, which would otherwise be inaccessible to 
them. However, such novel agents come with limited knowledge of their 
toxicity profile or anti-tumour activity. This has been one of the main reasons 
for the historically low referral rates of patients with advanced ovarian cancers 
to specialist phase I clinical trial units, in contrast to other malignancies. Yet in 
recent years, a number of drugs have been developed to inhibit targets or 
pathways known to be critical drivers of ovarian cancer, leading to increased 
phase I trial referrals for such patients [2-8]. 
 
There are several factors that have been established as predictors of 
response to further chemotherapy, and overall prognosis. Arguably, the most 
important of these historically is the platinum chemotherapy status, with 
patients defined as platinum-sensitive demonstrating improved anticancer 
responses to chemotherapy, and longer overall survival compared with 
patients with platinum-resistant disease. The platinum status has also been 
demonstrated to influence response rates to molecularly targeted agents, 
such as poly(ADP-ribose) polymerase (PARP) inhibitors, where early studies 
of olaparib showed response rates of 69% in those with platinum-sensitive 
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disease, compared with 45% and 23% in the platinum-resistant and refractory 
cohorts respectively [9]. Recent studies have investigated the role of somatic 
aberrations in ovarian cancer oncogenesis, with each histological subtype 
demonstrating distinct patterns of genomic abnormality prevalence within 
different pathways [10-20]. This molecular heterogeneity offers potential 
therapeutic targets for novel molecularly targeted agents in patients with 
advanced ovarian cancers beyond the current standard chemotherapeutic 
options [21].  
 
Data on treatment outcomes for patients with advanced ovarian cancers 
participating in early phase clinical trials are currently limited. We therefore 
reviewed our experience of patients with advanced ovarian cancers referred 
for consideration of early phase clinical trials in the Phase I Drug 
Development Unit at the Royal Marsden Hospital, London, United Kingdom. 
The primary objective was the identification of predictors of clinical benefit. 
Secondary objectives included the assessment of toxicity and antitumor 
activity of such experimental trial agents in our series of patients. Herein, we 
report our findings of the treatment outcomes for our patients, together with 
independent indicators of response. 
 
PATIENTS AND METHODS 
We conducted a retrospective review of the electronic patient records (EPR) 
of all patients with advanced ovarian cancers (or fallopian tube or primary 
peritoneal malignancies), treated on one or more phase I clinical trials within 
the Drug Development Unit at the Royal Marsden NHS Foundation Trust 
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between June 1998 and October 2010. Data on patient follow-up were 
collected until death or censored at June 2013, whichever was earlier. This 
retrospective study and all clinical trials included within it, were approved by 
the Royal Marsden Research and Development Committee; and all patients 
had provided their written informed consent prior to enrollment onto their 
respective clinical trial. Allocation to a clinical trial for all patients was made 
after consideration of individual clinical, radiological and laboratory data. 
Several phase I trials had specific mandatory eligibility criteria such as the 
presence or absence of germline genetic mutations. If the patient was eligible 
for more than one phase I trial, allocation was made based on patient 
preference and/or physician choice. At disease progression, a number of 
patients went on to be treated on further Phase I trials within the time 
assessed. Each allocation to a new Phase I trial was treated as a separate 
treatment event. 
 
All patients underwent baseline assessments before allocation and 
enrollment, including medical history, physical examination and laboratory 
tests as per trial protocol. The interval between allocation and study 
commencement was typically 3-4 weeks, during which time screening was 
performed according to specific protocols. After commencing on study, 
patients were reviewed regularly as per protocol. At each visit, detailed history 
and physical examination were performed, together with blood tests. 
Toxicities were assessed, graded, and considered for their relationship to 
study drug, with appropriate dose adjustment for toxicity if necessary. All 
patients had radiological review at baseline, following 2 cycles, and then as 
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defined by the trial protocol. Radiological antitumor response was reported 
using Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 or 1.1, as 
defined by the specific trial protocol. The Gynecologic Cancer InterGroup 
(GCIG) CA125 response was also assessed in patients with detectable levels 
of CA125 tumour marker. Treatment continued until disease progression, 
unacceptable toxicity, withdrawal of consent, or at the discretion of the 
treating clinician. 
 
Data collection 
The EPR was reviewed for each patient and the following data were collected 
for each patient: age at diagnosis, stage, grade, histological subtype, tumour 
estrogen receptor status, molecular profiling if undertaken, germline BRCA1/2 
mutation status, previous lines of anticancer therapy (drugs, dates and 
duration of treatment and best response), platinum chemotherapy status, 
ECOG performance status, number of metastatic sites, presence or absence 
of visceral metastases, hematological parameters, albumin, CA125 and date 
of death or last follow-up. 
 
Response assessments 
Radiological responses were assessed using RECIST criteria every 2-3 
cycles of therapy according to the trial protocol. A RECIST partial response 
(PR) was defined as ≥30% decrease in the sum of the largest diameter of 
target lesions, with a RECIST complete response (CR) occurring in those with 
disappearance of all target lesions. RECIST progressive disease (PD) was 
defined as a ≥20% increase in the sum of the longest diameter of target 
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lesions. RECIST stable disease (SD) was defined as neither sufficient 
shrinkage to meet PR criteria, nor sufficient growth to meet PD criteria, while 
prolonged RECIST stable disease was defined as SD for at least 4 months. 
 
GCIG CA125 response criteria are defined as ≥50% decrease in CA125 
levels compared to pretreatment levels, and the response must be confirmed 
and maintained for at least 28 days. Only patients with a CA-125 level of ≥2 x 
upper limit of normal within 2 weeks prior to commencing treatment were 
evaluable by GCIG CA125 criteria. Patients were also stratified by their 
platinum status. Patients were considered platinum sensitive if their disease 
progressed >6months after completing platinum based chemotherapy, 
platinum resistant if their disease progressed <6 months after completing 
platinum based chemotherapy; and platinum refractory if their disease 
progressed while on platinum chemotherapy. 
 
The RMH prognostic score was calculated as follows: albumin <35g/L, lactate 
dehydrogenase (LDH) > upper limit of normal (ULN); and the presence of >2 
sites of metastases all scored 1 point each; while albumin ≥35g/L, LDH <ULN 
and the presence of 2 or fewer sites of metastases each scored 0 points.  
Patients with an RMH score of 0 or 1 were considered good prognosis; while 
those with an RMH score of 2 or 3 were considered of poorer prognosis. 
 
Overall survival was measured from the date of starting treatment on the 
Phase I trial until death from any cause or last follow-up. Trial duration was 
measured from the day of starting treatment, until the last dose of treatment. 
9 
 
 
Statistical considerations 
The demographic and clinical characteristics of patients were summarized 
using descriptive statistics. The association between categorical variables and 
responses was assessed using the Fisher exact test. Multivariate analysis 
was used to identify predictors of response. 
 
RESULTS 
A total of 200 patients with advanced ovarian cancers were allocated to at 
least one phase I trial, with 281 allocations included between 06/1998 and 
10/2010. The majority of patients had high grade serous tumors (129/200; 
64.5%), with other histological subtypes including carcinosarcomas, granulosa 
cell tumors and undifferentiated ovarian cancer. Patients mainly had either 
platinum resistant or refractory disease (145/200; 72%), with the rest 
harboring platinum sensitive disease (55/200; 28%). The median age of the 
patients was 51 years (range 20-73 years). The median number of prior 
systemic anticancer treatments was 4 (range 1-14). 135 patients started at 
least one Phase I trial, for a total of 216 trial allocations. 65 of 200 (32%) did 
not begin their allocated trial, due to interval disease progression (63/65 [97%] 
patients) or patient choice (2/65 [3%] patients). The median time from trial 
allocation to commencing treatment was 23 days (range 1-64 days). Germline 
BRCA1/2 mutation status was known in 62/200 (31%) patients (of which 
53/62 [85%] patients had BRCA1/2 mutations, 9/62 [15%] patients were 
BRCA1/2 wildtype), and BRCA status was unknown in 138 patients. The entry 
to two of three PARP inhibitor trials was based on the presence of a 
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pathogenic BRCA1/2 mutation. The patient allocation to all other trials was not 
based on mutation status. Full demographic data is detailed in Table 1.  
 
Phase I clinical trials 
The phase I trials included in this study were classified into 11 groups based 
on the underlying mechanism of action of the investigational agent: PARP 
inhibitors, anti-angiogenic agents, histone deacetylase (HDAC) inhibitors, heat 
shock protein 90 (HSP90) inhibitors, phosphatidylinositol-3 kinase (PI3K) 
inhibitors, c-MET inhibitors, insulin growth factor-1 receptor (IGFR) inhibitors, 
chemotherapy/targeted therapy combinations, targeted therapy combinations, 
radiotherapy/targeted therapy combinations, RAS/RAF/MEK/ERK inhibitors, 
and others. 
 
Overall, 35/135 (26%) patients achieved objective antitumor responses in at 
least one trial, including 1 RECIST CR and 34 RECIST PR. Prolonged stable 
disease >4 months was observed in a further 21 patients, for an overall 
patient clinical benefit rate (CBR) of 56/135 (41%). The mean trial duration 
was 5.8 months (0.35-53 months). Two patients had a RECIST PR to their 
initial phase I trial therapy, and prolonged RECIST stable disease on their 
subsequent phase I trial. By patient trial allocations, there was an anticancer 
response rate of 35/216 (16%), and an overall CBR of 58/216 (27%). Mean 
overall survival was 32 months for RECIST CR/PR pt v 3.2 months, for 
patients who did not start treatment due to PD (p<0.0001). 
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Baseline clinical factors of antitumor response 
We assessed a range of baseline clinical factors to ascertain whether they 
differed significantly between patients who responded versus those who did 
not start treatment due to progressive disease. We identified multiple clinical 
factors that differed between these two groups, many of which correlated with 
patients with heavy disease burdens, or those who were heavily pretreated 
with prior chemotherapy regimens (Table 2). Women with platinum-sensitive 
disease were more likely to start a phase I trial than those with platinum-
resistant or refractory disease (p=0.0016). Those with platinum-sensitive 
disease were also more likely to respond to their phase I trial therapy 
(p<0.0001). The presence of a germline BRCA1/2 mutation was also an 
indicator of antitumor response across all treatment categories (p<0.0001). 
The mean RMH prognostic score was also significantly different between 
responders versus those with progressive disease (p<0.0001) 
 
Individual phase I trial outcomes 
PARP inhibitors 
78 patients with advanced ovarian cancers were allocated to 1 of 3 PARP 
inhibitor trials with 63 patients beginning treatment. RECIST responses 
occurred in 18 patients (28.5%), with a median duration of response of 21 
months (range 4.5-75 months). A further 13 patients experienced prolonged 
RECIST stable disease, for a clinical benefit rate (CBR) of 49%. Patients with 
a BRCA1/2 germline mutation had a higher RECIST response rate than those 
with unknown BRCA1/2 mutation status (16/47 [34%] vs 2/16 [12%], 
p<0.0001), as did those with platinum-sensitive disease (11/24 [46%] vs 7/39 
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[18%], p=0.039). The median time to progression among all patients was 4 
months (range 1.3-75).  
 
Anti-angiogenic agents 
A total of 64 patients were allocated to treatment with 1 of 5 anti-angiogenic 
drugs, of which 42 began treatment. There were 9 RECIST responses (21%), 
and 10 patients with stable disease >4 months, for a CBR of 45%. There were 
22 patients allocated to an anti-angiogenic agent who did not start treatment 
due to disease progression. There was a higher response rate amongst those 
who were platinum sensitive (p<0.0001), but no other features were noted to 
predict response. 
 
PI3K-AKT pathway inhibitors 
There were 32 patients allocated to treatment with drugs targeting the 
PI3Kinase pathway, with all patients platinum resistant at the time of entry to 
the trial. More than half of the patients allocated (56%) did not begin 
treatment, due to interval disease progression. There were no RECIST 
responses seen, although 2 patients (14%) had prolonged stable disease. 
 
Molecularly targeted agent and chemotherapy combinations 
There were 6 trials assessing the combination of chemotherapy (platinum or 
taxane), combined with a targeted agent, with a total of 43 patients allocated 
to treatment, 32 of whom began treatment. There were RECIST responses in 
14 patients (44%), with SD>4 months in a further 3 patients, for a CBR of 
53%. These treatments had higher rates of toxicity, with 4 patients (12.5%) 
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withdrawing from treatment after the first cycle due to neutropenic sepsis. The 
patients with platinum sensitive disease had significantly higher response 
rates, irrespective of the chemotherapy agent used (50% vs 25%, p=0.0001). 
 
Other early phase clinical trials 
There were small numbers of patients treated with each of the remaining 
classes of drugs. There was only 1 other PR (RECIST) noted, in a patient 
treated with a combination of 2 targeted agents. The full details are shown in 
Supplementary Table 1. 
 
Systemic therapies after phase I trials 
There were 142 patients (71%) who went on to receive at least 1 further line 
of systemic treatment after their Phase I trial, with 82 patients (41%) receiving 
2 or more further lines of treatment. The full list of subsequent treatment is 
shown in Table 3. 
 
Trial-related toxicities 
The patients treated on the Phase I trials generally tolerated treatment well, 
with the majority of reported toxicity either Grade 1 or Grade 2 (332, 90%). 
This was generally managed with a dose reduction or treatment interruption. 
There were 36 Grade 3/4 toxicities. All of the Grade 4 toxicity occurred in 
patients treated on the chemotherapy/targeted agent combination treatments. 
There were no Grade 5 toxicities. The full toxicity data are shown in Table 4. 
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DISCUSSION 
Our experience represents one of the largest reported cohorts of ovarian 
cancer patients treated within Phase I trials. Our report covers a wide range of 
Phase I trials, from early combined chemotherapy/novel agent combinations, 
through to recent dual targeted agent trials, reflecting the emergence of 
targeted treatment, and the increasing interest in ovarian cancer as a tumour 
with a number of potentially targetable pathways. This has led to the 
development of drugs such as bevacizumab, which have resulted in 
significant improvements in outcome for patients at multiple points in the 
treatment pathway[22-25]. The time period (1998 – 2010) also included the 
first trials of PARP inhibitors in ovarian cancer patients. The first of these, 
olaparib, has received EU and FDA approval and is available in a number of 
countries as an option for maintenance treatment in woman following platinum 
sensitive relapse. Studies are ongoing for other PARP inhibitors, including a 
wider range of indications [26-30].  
 
The majority of the ovarian cancer patients referred for Phase I trials in our 
series were heavily pre-treated. This is in keeping with studies such as 
Brunetto et al, who reported that one of the most common reasons for referral 
to Phase I units in colorectal cancer patients was exhaustion of conventional 
chemotherapeutic options[31]. Despite this, 41% of patients in our series went 
on to have multiple further lines of systemic treatment, with either Phase I 
agents, or other agents. This is contrary to the widely perceived notion of 
Phase I trials as the ‘final option’ for such patients. 
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One of the most striking features of our study was the number of patients 
allocated to a trial, but who had rapid progression of disease, rendering them 
ineligible. This was most commonly due to a deterioration in their performance 
status, or development of new metastatic disease that impacted upon 
haematological parameters. In our study, we identified a number of factors 
that differed significantly between patients with rapidly progressive disease, 
and those who responded to treatment; and further validated the RMH 
prognostic score as a discerning factor in identifying those who may benefit 
from Phase I trials [32, 33]. In general, these factors were all indicative of a 
greater burden of disease, such as number of metastatic sites, baseline 
albumin and CA-125 levels; and ECOG status. This suggests that many 
patients were referred at a point in their disease process where they were 
unable to benefit from such targeted agents, many of which have a cytostatic, 
rather than cytocidal effect. Such patients were also at risk of common 
ovarian cancer complications, such as bowel or gastric outlet obstruction, 
limiting the use of orally administered agents. In contrast, those with other 
established predictors of response, such as platinum sensitivity and fewer 
prior lines of therapy were more likely to respond to their Phase I trial. We 
therefore suggest that the optimal timing to consider Phase I trials may be 
earlier in the patient’s journey, before they have exhausted all standard 
chemotherapeutic options. Such patients are not only generally in better 
physical shape, able to withstand potentially unexpected side effects, but also 
have the option of commencing alternative systemic treatments if they do not 
respond to their Phase I trial agent.  
 
16 
 
There is increasing interest in routine molecular testing of all patients 
considering Phase I trials, so that germline and somatic mutation data can be 
incorporated into trial selection[34]. This molecular matching of target and 
agent has been reported to significantly improve both progression-free 
survival (3.9 vs 2.2 months), and median survival (11.4 vs 8.6 months) 
compared to unmatched therapy [35]. Matched therapy was also associated 
with a higher objective response rate of 12%, compared with only 5% in those 
with unmatched cohorts. In our cohort, dating back to 1998, only patients 
entering two of three PARP inhibitor trials were selected for presence of a 
pathogenic BRCA mutation, with no other molecular matching performed at 
that time. With improvements in technology molecular profiling for targetable 
mutations is now offered to all patients in our Phase I unit, to maximize patient 
benefit from treatment. Despite this, many patients still do not have 
therapeutically targetable mutations, limiting the benefit of this strategy. 
 
We did not observe any responses in the 14 patients treated with agents 
targeting the PI3 kinase pathway, with only 2 patients demonstrating 
prolonged stable disease. This contrasts with other studies that have reported 
responses with these agents in patients with advanced ovarian cancer [36].  
PIK3CA mutations are relatively common, reported in 20% of endometroid 
ovarian cancer, and up to 33% of clear cell patients [11, 15, 37]. Amplification 
of PIK3CA is reported in 40% of high grade serous patients [11]. Although we 
do not have specific mutation information on the patients treated, all were high 
grade serous or clear cell patients, making it likely that patients with 
alterations in this pathway were represented in this cohort. However, all of the 
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patients treated had platinum resistant/refractory disease. This was a 
predictor of response across other treatment groups, and it is possible this 
may have impacted on the response rates. It is also notable that we did not 
collect dosing information, and therefore these patients may not have 
received sufficient drug to see efficacy. 
 
There are several limitations to our study. This was a retrospective study, with 
an under-representation of clear cell and endometroid histologies; and an 
over-representation of rare subtypes, such as small cell ovarian carcinoma. 
There was also a significant proportion of undifferentiated carcinoma, which in 
part reflects the time period during which patients were diagnosed. Another 
limitation of the study is the reported toxicity, which was based on 
retrospective collection of data. Each Phase I patient had toxicity recorded 
and graded with every visit, but concurrent dose levels were not collected, 
thereby limiting interpretation of these data. 
 
Our study has demonstrated that ovarian cancer patients do benefit from 
Phase I trials, with objective response rates of 26% in those starting 
treatment. This response rate was higher in those with platinum sensitive 
disease, most of whom were treated at an earlier stage in their disease 
pathway than those with platinum resistant or refractory disease. Many of our 
patients went on to receive multiple lines of treatment after their Phase I trial, 
including both other Phase I drugs, and further chemotherapy. This response 
rate may improve further with the use of routine molecular profiling, and 
matching of therapy. We propose that patients may benefit from a more 
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collaborative approach, with early review by a Phase I unit. Such patients 
could undergo molecular profiling early, with the aim that they move to an 
appropriate Phase I trial earlier, while maintaining the option of further 
chemotherapy or other Phase I trials to maximize treatment options. 
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 TABLES 
 
Table 1. Patient demographics 
Demographic Variable No. of Patients (%) 
Age <40 23 (11.5%) 
 40-49 60 (30%) 
 50-59 72 (36%) 
 60-69 41 (20.5%) 
 ≥ 70 4 (2%) 
Tumour histology Serous 129 (64.5%) 
 Clear Cell 6 (3%) 
 Endometroid 3 (1.5%) 
 Mucinous 6 (3%) 
 Mixed 8 (4%) 
 Undifferentiated 27 (13.5%) 
 Carcinosarcoma 6 (3%) 
 Granulosa Cell 5 (2.5%) 
 Other 10 (5%) 
Prior lines of treatment 1 20 (10%) 
 2 33 16.5%) 
 3 45 (22.5%) 
 4 36 (18%) 
 5-6 47 (23.5%) 
 7-8 13 6.5%) 
 9+ 6 (3%) 
Platinum status Sensitive 51 (25.5%) 
 Refractory/resistant 145 (72.5%) 
 Not Recorded 4 (2%) 
Visceral metastases Present 85 (42.5%) 
 Absent 115 (52.5%) 
ECOG Performance Status 0 45 (22.5%) 
 1 142 (71%) 
 2 10 (5%) 
 >2 3 (1.5%) 
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Table 2 – Potential predictors of response to phase I trial therapies 
Factor Assessed p value 
No. prior lines of treatment p=0.02 
Mean albumin (g/L) at baseline p<0.001 
No. metastatic sites  p = 0.04 
Mean RMH score p<0.001 
RECIST response to preceding treatment p<0.001 
ECOG status at baseline p=0.02 
Baseline hemoglobin p<0.001 
Baseline CA-125 p=0.02 
Baseline LDH level p=0.43 
Baseline platelet level p=0.11 
Baseline neutrophil level p=0.32 
Baseline creatinine level p=0.14 
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Table 3. Post-phase I trial systemic antitumor therapies 
No. of subsequent 
treatments 
No. of patients (%) 
0 58 (29%) 
1 60 (30%) 
2 42 (21%) 
3 18 (9%) 
4 7 (3.5%) 
5 4 (2%) 
7 2 (1%) 
Not recorded 7 (3.5%) 
Still on Phase 1 trials* 2 (1%) 
*As of 30 June 2013 
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Table 4. Reported drug-related toxicities 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Fatigue 85 29 12 (6*)  
Nausea 45 19 1 (1*)  
Vomiting 14 6   
Dyspepsia 8 1   
Rash 12  5  
Diarrhea 29 6 3  
Constipation 11 7   
Anorexia 11 6   
Neutropenia 3 5 1 (1*)  
Anemia 1 3 1 (1*)  
Thrombocytopenia 2 4 4 (2*)  
Neutropenic sepsis    4 (4*) 
Non-neutropenic 
infection 
 2 1  
Hypertension 3 2 1  
Abdominal pain 4 4 1 (1*)  
VTE  1   
LFT changes 2  2  
Edema 5 2   
 
* denotes G3/4 toxicity observed in chemotherapy combination trial 
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Supplementary Table 1. Patient outcomes from remaining trials* 
Regimen PR SD PD Not 
Started 
Total 
HDAC inhibitors 0 6 2 5 13 
HSP-90 inhibitors 0 0 0 1 1 
cMET inhibitors 0 0 0 1 1 
IGFR inhibitors 0 0 3 5 8 
Targeted 
combinations 
1 1 0 1 3 
Ras/Raf/Mek 0 2 1 0 3 
Radiation 
combination 
0 0 1 0 1 
Others 0 6 10 18 34 
Total 1 15 17 31 64 
 
*Excluding phase I trials of PARP inhibitors, anti-angiogenics, PI3K pathway 
inhibitors 
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